Generic Liraglutide Approved

A GLP-1 drug helps people feel full and eat less, and the Food and Drug Administration has now cleared a generic liraglutide shot for weight loss. (fda.gov; pharmacytimes.com) Teva said on August 28, 2025, that the FDA approved and launched its generic version of Saxenda, the brand-name liraglutide injection used for chronic weight management. Teva called it the first generic GLP-1 specifically indicated for weight loss in the U.S. market. (tevapharm.com) The approved use matches Saxenda’s label: adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition, plus patients ages 12 and older who weigh more than 60 kilograms and meet obesity cutoffs. The drug is meant to be used with a reduced-calorie diet and increased physical activity. (fda.gov; fda.gov) Liraglutide is not the newer weekly shot that has dominated demand in obesity care. Saxenda is a once-daily injection, and its label says patients should not use it with other liraglutide products or with any other GLP-1 receptor agonist. (fda.gov) The FDA had already approved a different generic liraglutide product on December 23, 2024, but that one referenced Victoza for blood-sugar control in type 2 diabetes, not weight loss. The agency said at the time that liraglutide and some other GLP-1 medicines were in shortage and that it prioritizes generic reviews for drugs in shortage. (fda.gov) That distinction matters at the pharmacy counter because the same active ingredient can sit under different brand names, doses, and approved uses. The Saxenda label targets chronic weight management at 3 milligrams daily after dose escalation, while the Victoza-linked generic approval was tied to diabetes treatment. (fda.gov; fda.gov) FDA records also show that approval does not guarantee immediate supply. The agency’s first-generic database says approved drugs are not always available on or after the approval date, and Teva said Saxenda had annual sales of $165 million as of June 2025. (fda.gov; tevapharm.com) The FDA treats first generics as a public-health priority because they can widen treatment options and lower costs, but the agency’s own labeling still makes the basics clear: this is a daily pen, it has specific obesity criteria, and it is not meant to be combined with another GLP-1. (fda.gov; fda.gov)